Chemours Co (CC) director Cranston purchases 6,000 shares in open-market trade

Rhea-AI Filing Summary

Chemours Co director Mary B. Cranston purchased 6,000 shares of Chemours common stock in an open-market transaction on 2026-08-07 at a price of $15.825 per share. Following this purchase, she reports beneficial ownership of 113,140.9469 shares, which includes directly owned shares, restricted stock units, and dividend equivalent units.

Insider Trade Summary

Net Buyer: 6,000 shares

Net Buy 1 txn

Insider CRANSTON MARY B

Role Director

Bought 6,000 shs ($95K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	6,000	$15.825	$95K

Holdings After Transaction: Common Stock — 113,140.9469 shares (Direct)

Footnotes (1)

1. F1. Includes directly owned shares, restricted stock units and dividend equivalent units.

Key Figures

Shares purchased: 6,000 shares Purchase price per share: $15.825 per share Total shares owned after transaction: 113,140.9469 shares +1 more

4 metrics

Shares purchased 6,000 shares Common stock bought by director Mary B. Cranston on 2026-08-07

Purchase price per share $15.825 per share Open-market or private transaction purchase price for Chemours common stock

Total shares owned after transaction 113,140.9469 shares Beneficial ownership including directly owned shares, restricted stock units and dividend equivalent units

Net buy shares in filing 6,000 shares Net buy direction across all reported transactions in this Form 4

Key Terms

restricted stock units, dividend equivalent units, beneficial ownership

3 terms

restricted stock units financial

"Includes directly owned shares, restricted stock units and dividend equivalent units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

dividend equivalent units financial

"Includes directly owned shares, restricted stock units and dividend equivalent units."

Dividend equivalent units are bookkeeping credits that mirror cash dividends paid on actual shares, granted to holders of stock-based awards such as restricted stock units or deferred compensation. They matter to investors because they increase a company’s reported employee compensation cost and can lead to issuance of more shares or cash payouts over time, similar to extra pay linked to ownership that affects shareholder dilution and corporate cash flow.

beneficial ownership financial

"Following this purchase, she reports beneficial ownership of 113,140.9469 shares."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 04:10 PM Accepted by SEC EDGAR 08/11/2026 - 04:10 PM Learn about SEC filing dates

FAQ

What insider transaction did Chemours Co (CC) disclose for Mary B. Cranston?

Chemours Co reported that director Mary B. Cranston purchased 6,000 shares of common stock on 2026-08-07. The shares were bought in an open-market transaction at $15.825 per share, increasing her reported ownership stake.

How many Chemours Co (CC) shares does Mary B. Cranston own after this transaction?

After the reported purchase, Mary B. Cranston beneficially owns 113,140.9469 Chemours shares. This total includes directly owned shares, as well as restricted stock units and dividend equivalent units referenced in the filing footnote.

Was the Chemours Co (CC) insider trade by Mary B. Cranston a purchase or a sale?

The reported insider transaction by Mary B. Cranston was a purchase of Chemours common stock. She acquired 6,000 shares in an open-market or private transaction coded as a “P” purchase on the Form 4.

At what price did Mary B. Cranston buy Chemours Co (CC) shares?

Mary B. Cranston bought Chemours common stock at a price of $15.825 per share. The transaction involved 6,000 shares on 2026-08-07, as characterized in the Form 4 as a purchase in an open-market or private transaction.

Does the Chemours Co (CC) Form 4 mention any derivative or option exercises by Mary B. Cranston?

The Form 4 for Mary B. Cranston reports only a single non-derivative purchase of common stock. The derivativeSummary is empty, indicating no option or other derivative security exercises were reported in this particular filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CRANSTON MARY B

(Last) (First) (Middle)

C/O THE CHEMOURS COMPANY

1007 MARKET STREET

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Chemours Co [ CC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2026		P		6,000	A	$15.825	113,140.9469(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes directly owned shares, restricted stock units and dividend equivalent units.

	/s/ Eric Stein, Attorney-in-Fact	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)